ArticleJournal of biophotonics2025
External Validation of Raman Spectroscopy for Lyme Disease Diagnostics.
Article in Journal of biophotonics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Lyme disease (LD), caused by Borreliella burgdorferi, is the most common tick-borne illness in the United States, yet early-stage diagnosis remains challenging due to the limitations of current serological diagnostics. Raman spectroscopy (RS), paired with partial least squares discriminant analysis (PLS-DA), showed promise as an alternative diagnostic tool. Using RS, we analyzed 107 coded human blood samples (42 LD-positive and 65 LD-negative) obtained from the Lyme Disease Biobank. PLS-DA models showed nearly perfect internal validation performance with a sensitivity and specificity of 97.1% and 100.0%, respectively, indicating robust predictive capabilities. External validation of the developed chemometrics model with 80/20 training/validation split of all spectra gave true positive rates of 92.7% and 87.3% for serological positive and negative spectra, respectively. These findings highlight the potential of RS as a rapid and noninvasive diagnostic platform for LD, particularly when integrated with machine learning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.